VHIRhttp://www.vhir.org/salapremsa/noticies/noticies_paginacio.asp?page=1&mv1=5&mv2=3es-esIRHUV15Researchers identify a gene associated to higher survival from sepsis due to pneumonia (30/01/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2015&num=17&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0017\2015_0017_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Researchers from the European Society of Intensive Care Medicine (ESICM) have identified a gene located in chromosome 5 that is associated to higher risk of survival from sepsis due to pneumonia or intra-abdominal infection contracted outside the hospital. Dr. Jordi Rello, head of the Clinical Research and Innovation in Pneumonia and Sepsis (CRIPS) group at Vall d’Hebron Institute of Research (VHIR), led the Spanish participation in this study published recently in The Lancet. The aim of the research was to determine whether the genetic factors contribute to the progress of the disease. With this purpose, researchers conducted the first genome-wide association study carried out in patients admitted to intensive care units with sepsis due to pneumonia. They analyzed up to 1.500 patients of whom the 23 per cent died within the intensive care unit admission. Among the results obtained, scientists identified this gene of the chromosome 5, called FER, that is carried by nearly the 20 per cent of the European population. The genetics of these people protects them from the progress of the disease and improves their response to the current treatments. Thanks to this discovery, Dr. Rello reports that they could “develop biomarkers for risk stratification, as well as potential novel targets for therapy or prevention of the complications”. Pneumonia is the main cause of severe sepsis, which is the inflammatory response of the body to the infections. Despite the latest advances on research, Dr. Rello assures that the mortality rate of sepsis due to pneumonia has never fallen from the 20 per cent. </td></tr></table>comunica@vhir.org (VHIR)Fri, 30 Jan 2015 00:00:00 GMTVall d'Hebron hosts an exhibition on rare diseases research (29/01/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=13&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0013\2015_0013_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The maternal-pediatrics area of the Vall d’Hebron University Hospital will host from the 2nd to the 19th of February the exhibition Menys rares (‘less rare’ in English), dedicated to research on rare diseases. The exposition is organized by the Catalan association of scientific communication (ACCC), the Center for Biomedical Network Research of Rare Diseases (CIBERER) and the National Genome Analysis Centre (CNAG). Menys rares was opened in 2014 at the Sagrada Familia Library in Barcelona, and includes a summary of the research carried out at Vall d’Hebron Institute of Research (VHIR) in more than one hundred rare diseases, in which Vall d’Hebron is the leader in Spain. The exhibition shows the reality of these diseases that include between 5,000 and 7,000 different types of pathologies. The European Union classified as ‘rare diseases’ those that affect less than 1 individual out of 2,000, according to orpha.net. The origin of most of these diseases is genetic and there is a lack of medical and scientific knowledge about them. For that reason, the research of therapies and drugs is essential.&nbsp; In Spain there are several research groups that work together through entities such as CIBERER (from the Instituto de Salud Carlos III), or CNAG. As 2013 was the International Year on Rare Diseases, both institutions, together with the ACCC, decided to promote the research carried out by their scientists in these diseases. The aim of the exhibition is to show to the society what rare diseases are really all about, and what researchers are currently doing to combat their effects. With particular cases, such as Lowe, <a style=" font-size: 8pt; font-family: 'Verdana', 'Geneva', sans-serif; font-style: normal; font-weight: bold; color: </td></tr></table>comunica@vhir.org (VHIR)Thu, 29 Jan 2015 00:00:00 GMTAmics de Les Arts and Trepitja Garrotxa give more than 43,000€ for research in children diseases (28/01/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2015&num=12&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0012\2015_0012_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Catalan meat company Noel Alimentària, through its foundation called ‘Albert Bosch’, has given the 43.508 euros raised in 2014, for the research in children diseases at Vall d’Hebron Institut de Recerca (VHIR). The funds were collected in the Trepitja Garrotxa race and two concerts of Els Amics de les Arts, who have played today for the children with cancer at Vall d’Hebron Hospital. The Catalan band rose up to 38.000 euros in two benefit concerts, hosted in Olot and Sant Cugat del Vallès, and organized by the Albert Bosch Foundation in order to contribute to child cancer research at VHIR, headed by Dr. Sánchez de Toledo. Beside these concerts, during 2014 the Foundation organized several activities in La Garrotxa region, such as the first ultra-resistance race ‘Trepitja Garrotxa’, with more than 80 participants and 5.650 euros collected. The Albert Bosch Foundation was created in 2004 by Noel Alimentària, with the aim of promoting medical research for child diseases and lupus. </td></tr></table>comunica@vhir.org (VHIR)Wed, 28 Jan 2015 00:00:00 GMTIronman for child cancer (27/01/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=11&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0011\2015_0011_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Alberto, Sergio, Víctor, Chelo and Ilde are the brave athletes who will run, swim and cycle the Lanzarote Ironman that will take place on May 23rd. They will compete with a great objective: to raise funds to advance in child cancer research at Vall d’Hebron Institut de Recerca (VHIR). “We aim to transmit our energy and support to all the children who are fighting against cancer”, said Alberto, who opened the challenge in the fundraising site migranodearena.org. They’d like to raise 2,500 euros that will directly go to the Translational Research in Child Cancer group, led by Dr. Josep Sánchez de Toledo at VHIR. The athletes are from León, Valencia and the Canary Islands, they have participated in several Ironman, but they have never visited the Pediatric Oncology Unit at Vall d’Hebron University Hospital. However, they are convinced that they want to contribute to help the weakest and reach the 0 mortality rate in child cancer. The research group at VHIR is dedicated to investigate new treatments and diagnosis methods to combat cancer during childhood. The survival rate to this disease is high, close to the 80%, but some neoplasias show lower rates. In this sense, further research is needed in order to find new therapies that could improve the general prognosis and the survival high-risk patients. </td></tr></table>comunica@vhir.org (VHIR)Tue, 27 Jan 2015 00:00:00 GMTDr. Ariadna Laguna has been granted by the Tatiana PGB Foundation to study Parkinson's disease (23/01/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=9&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0009\2015_0009_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Tatiana Pérez de Guzmán el Bueno Foundation has granted with one out of the eight neuroscience research grants Dr. Ariadna Laguna, researcher of the Neurodegenerative Diseases group at Vall d’Hebron Institute of Research (VHIR). The project, entitled “Study of the transcriptional profile in a sub-group of prodromal patients with Partinson’s disease”, will last 3 years and has been funded with 40,000 euros. The aim of the study is to identify molecular pathways, genes and microRNAs deregulated in two types of patients who have not displayed yet the motor symptoms, but have already suffered other changes that precede the onset of the disease. In order conduct the study, Dr. Laguna will carry out a cutting edge RNA sequencing technique from isolated neurons of post-mortem brain tissue from both groups of patients. With the results of the study, VHIR researcher expects that “we could better understand the etiology and pathogenesis of the disease and correlate the transcriptional changes with the clinical and neuropathological data”. Despite the latest advances in Parkinson’s disease research, the only treatment available is symptomatic and is yet far away to avoid the onset of the disease and its progression. </td></tr></table>comunica@vhir.org (VHIR)Fri, 23 Jan 2015 00:00:00 GMTVHIR researchers launch a bank of primary immunodeficiencies samples (21/01/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2015&num=8&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0008\2015_0008_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Infection in Immunocompromised Pediatric Patients group and the Immunology group at Vall d’Hebron Institute of Research (VHIR) have started to collect blood samples from patients with primary immune deficiencies and their relatives who also participated in the Immunology Bank of the HUVH Biobank. The aim of the groups is to become the biobank of reference in these diseases in Catalonia. VHIR researchers will collect samples of the 3 types of patients that they treat in the Pediatric Infectious Diseases and Immunodeficiencies Unit (UPIIP): patients with a clinically compatible case and genetic confirmation; patients with primary immunodeficiencies in which the gene that causes the disease is still unknown, and patients with an unknown type of immunodeficiency. All the samples will be collected during routine blood tests, and with parental consent. In this case, researchers will also offer to the patients’ relatives the opportunity of being studied in order to carry out genetic studies with more diagnostic ability. With the samples collected in a standardized model, researchers will investigate these diseases, optimize the diagnosis and offer genetic counseling to the closest relatives, in collaboration with the Clinical Genetics Area at Vall d’Hebron hospital. This project has the support of the Catalan association of patients with immunodeficiencies (ACADIP), the BCN-PID Foundation and the fundraising campaign "tots amb Didac", that has raised over 25,000 euros for the research at VHIR in these rare diseases. Primary Immunodecifiencies at Vall d'Hebron <p style=" text-align: left; text-indent: 0px; padding: 0px </td></tr></table>comunica@vhir.org (VHIR)Wed, 21 Jan 2015 00:00:00 GMTSchizofrenia, major depression and bipolar disorder share genetic risk factors (20/01/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2015&num=6&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0006\2015_0006_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Psychiatric Genomics Consortium, from which are members researchers of the Psychiatry, Mental Health and Addictions group at Vall d’Hebron Institute of Research (VHIR), have published a study that concludes that psychiatric disorders such as schizophrenia, major depression and bipolar disorder share genetic risk factors and variations associated with the immune system. The study has been published this week in Nature Neuroscience. Researchers carried out a genome-wide association study to analyze the genetic profile from over 60,000 participants from the different countries of the consortium. Once they compared the results, they discovered that the three adult psychiatric disorders implicate neuronal, immune and histone pathways. According to Dr. Josep Antoni Ramos-Quiroga, VHIR researcher who has participated in the study, “the knowledge of the molecular pathways involved in these diseases will enable the development of more specific therapeutic targets”. Nowadays, the etiology of these diseases is largely unknown, there is a lack of biomarkers, and the diagnosis is based exclusively in clinical symptoms. VHIR researchers provided data about the attention deficit-hyperactivity disorder (ADHD), because the study also compared the genetic profiles of people with other psychiatric disorders. </td></tr></table>comunica@vhir.org (VHIR)Tue, 20 Jan 2015 00:00:00 GMTAbdominal distension can be corrected by muscular control techniques (15/01/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2015&num=5&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0005\2015_0005_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Researchers from the Physiology and Pathophysiology of the Digestive Tract group at Vall d’Hebron Institut de Recerca (VHIR), led by Dr. Fernando Azpiroz, have proved that abdominal distension can be prevented by correcting thoracic and abdominal muscular activity, as the cause is a voluntary muscular response, induced by small changes in the intestinal contents. The study, published in Gastroenterology, is the last phase of a 15 year research that has proved that neither gas, nor the abdominal content are responsible of the abdominal bloat. VHIR’s researchers carried out a prospective study with 45 patients with functional bowel diseases and abdominal distension episodes, which sometimes were asymptomatic when visiting the hospital. “By performing an abdomino-thoracic computed tomography, to see the shape of the abdomen, and an electromyography, to verify muscular activity, we saw that patients with distention have larger thorax filling, with a wall elevation, and anterior abdominal wall protrusion”, explained Dr. Azpiroz. After realizing it was a muscular problem, the researchers instructed the patients (1-3 lessons) on how to revert the situation, relaxing the diaphragm and intercostal muscles, and also contracting the anterior abdominal wall. As a result, patients corrected abdominal distention by reducing the diaphragm’s and intercostal muscles’ activity. Both for diagnosis and for teaching purposes, VHIR’s researchers have been using “a very sophisticated system, precise and expensive, that allows us to control all the variables and show the patients their muscle’s reactions”, says Dr. Azpiroz. This means that now it’s important to validate the system in a controlled trial, and that there is still a lot of work to do in order to simplify the procedure before it can be transferred to clinical practice. Anyhow, the experimental treatment has proved that abdominal distension is under voluntary control and can be reverted. The finding also reveals why patients with abdominal distention usually feel they lack air. What really happens is that they have difficulty to breathe because their thorax is full of air, as it happens with asthmatic and lung emphysema patients, and not oppressed by the abdominal contents as traditionally thought. Abdominal distension is one of the main symptoms of functional gut diseases, such as irritable bowel syndrome, abdominal bloating or functional dyspepsia, and is the reason of nearly 40% of the gastroenterology consultations. VHIR’s researchers observed this muscular change over 5 years ago, after noticing that in patients with distension both gas volume in the bowel and viscera in the abdominal cavity show a slight increase that, by itself, do not justify distension.&nbsp; </td></tr></table>comunica@vhir.org (VHIR)Thu, 15 Jan 2015 00:00:00 GMTDr. Marta Ribases receives one of the American NARSAD grants to study ADHD (14/01/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=4&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0004\2015_0004_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Brain &amp; Behaviour Research Foundation has awarded Dr. Marta Ribases, researcher of the Psychiatry, Mental Health and Addictions group at Vall d’Hebron Institute of Research (VHIR), with one of the National Alliance for Research on Schizophrenia and Depression (NARSAD) grants. The aim of the project, endowed with nearly 65,000 dollars for the next two years, is the identification of biomarkers for Attention Deficit Hyperactivity Disorder (ADHD), through high-throughput next generation sequencing. Specifically, she will compare genome-wide microRNA expression profiles in patients with ADHD and controls. ADHD is the most common childhood onset psychiatric disorder; it affects 6% of children and manifests as symptoms of inattention, hyperactivity and/or impulsivity. The etiology of ADHD is complex, with the involvement of both genetic and environmental factors. According to Dr. Ribases, “given the lack of consistency of results obtained in genetic studies of susceptibility variants, the analysis of biological markers, such as miRNA or gene expression, which can reflect the combined effect of genetic predisposition and environmental risk factors, represents an alternative approach to identify potential risk factors involved in the disease”. NARSAD grants are addressed to young, independent and distinguished investigators in the field of mental health. The grants keep the former name of the Brain &amp; Behaviour Research Foundation, which since 1987 has awarded over 320 million dollars for research projects related to mental illness. </td></tr></table>comunica@vhir.org (VHIR)Wed, 14 Jan 2015 00:00:00 GMTThe AECC grants a study on child cancer at VHIR (12/01/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2015&num=3&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0003\2015_0003_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Spanish association for cancer research (AECC) in Catalonia has given one of the 5 grants of the institution to a study led by Dr. Aroa Soriano, member of the Translational Research in Child Cancer group at Vall d’Hebron Institute of Research (VHIR). Her study aims to determine the contribution of the extracellular kinase 5 (ERK5) in the aggressiveness of neuroblastoma, which is the most common solid type of tumor among children. According to Dr. Soriano, “the results of this project will be useful to obtain a biomarker of response to certain groups of patients that could response to the therapy based on the inhibition of the ERK5 kinase activity". The recent development of pharmacological inhibitors of ERK5 has positioned this kinase as a therapeutic target in many cancers among adults. However, it has never been analyzed in the case of child cancer. The prognosis of children with neuroblastoma is excellent in low risk patients, but worse in other stages. In fact, in the last 20 years, the survival of patients in the middle and high stages of the disease has not improved significantly and is among the 30 and 50%. For that reason, Dr. Soriano explains that “due to the existence of multiple mechanisms that cause the resistance to chemotherapy, and to the failure of current treatments, new therapeutic strategies are needed to treat the patients more effectively”. The project duration is 2 years, has been granted with 20,000 euros and will be developed in collaboration with the Protein Kinases and Signal Transduction in Neuronal Cells research group of the Universitat Autònoma de Barcelona (UAB). The AECC in Catalonia has granted a total of 5 Catalan research projects with 100,000 euros. </td></tr></table>comunica@vhir.org (VHIR)Mon, 12 Jan 2015 00:00:00 GMTMaria Salvadó has been awarded at the 25th International Symposium on ALS (08/01/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=2&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0002\2015_0002_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Maria Salvadó, neurologist and researcher of the Pheripheral Nervous Diseases group at Vall d’Hebron Institute of&nbsp; Research (VHIR), won the Scientific Poster Prize at the 25th International Symposium on Amyotrophic Lateral Sclerosis (ALS). The researcher of the group led by Dr. Josep Gámez presented in a poster the results of the role of the microloglia CX3CR1 gene as a modifying factor in the progression of the symptoms and the survival of ALS patients. According to one of the members of the jury, Prof. Linda Greensmith, “it was a clearly presented and well conducted study which identified a new genetic factor that influences the rate of disease progression and survival time in patients”. More than 800 international experts participated on December in this symposium which took place in Brussels, in order to present and discuss the latest advances in the fight against ALS. The cause of this disease is unknown and there is no cure or treatment available. It is characterized by the loss of motor neurons which cause rapidly progressive weakness, muscle atrophy and the death of the patients by breathing failure. </td></tr></table>comunica@vhir.org (VHIR)Thu, 8 Jan 2015 00:00:00 GMTVHIR in 2014 (31/12/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=277&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> We end a year full of scientific landmarks that will help to improve people’s health. ¿Do you want to read some of the main discoveries of VHIR researchers in 2014? We have created a Storify with some of the best news, tweets, pictures and videos of the year. To read it properly and on full screen, click on the following link: VHIR in 2014 Thanks to all of you who have made possible this great 2014. We wish you a happy new year!&nbsp; </td></tr></table>comunica@vhir.org (VHIR)Wed, 31 Dec 2014 00:00:00 GMTVHIR's director talks to the media about the past, present and future of the Institute (23/12/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=276&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0276\2014_0276_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> VHIR's Director, Dr. Joan Comella, was interviewed in several media to talk about the present, past and future of Vall d'Hebron Institute of Research (VHIR), coinciding with its 20th anniversary. Dr. Comella remembered the first years of research at Vall d'Hebron Campus, with all the problems and the illusion of those years, but also the hard work of all of the researchers and doctors that helped to begin the Institute. He also talked about the present, the good results and the best strategies to keep improving in the future. "We can only ask the researchers to be good doing research, not to be heroes", he reported to the journal Ara, highlighting that one of the functions of the Institute is to make all the work to help the researchers, so they only should do science. In the same interview, Dr. Comella confessed that "being the Director of the Institute is the best of my professional career", and showed his optimism regarding the potential of VHIR in the future. Dr. Comella was also interviewed in 8TV and BTV, together with VHIR researchers such as Dr. Simó Schwartz, first director of research at Vall d'Hebron, and Dr. Rafael Simó, president of the VHIR's Internal Scientific Council. Dr. Anna Meseguer, deputy director of basic and translational research at VHIR, also talked about the 20th anniversary of the centre, in this case in the webpage of the Barcelona city council. </td></tr></table>comunica@vhir.org (VHIR)Tue, 23 Dec 2014 00:00:00 GMT'Enzyme' will donate a Euro for each click to research in child cancer this Christmas (22/12/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=273&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0273\2014_0273_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Enzyme Advertising Group supports the research in child cancer at VHIR with an internet campaign that will raise 1 Euro for each click to the Christmas card on their web page. Enzyme is a professional services firm with international presence that provides consulting and technology advice joining together new challenges and business models. For each visit made to the Christmas card online, Enzyme will give 1 Euro to the A. Bosch Foudation that has supported VHIR’s work for many years, especially that related to research in child cancer. The firm will also raise 1 Euro for each ‘Like’ on their Facebook page, and for every new follower on their Twitter and Linkedin accounts. You have time to click for donations until the 24th of December. </td></tr></table>comunica@vhir.org (VHIR)Mon, 22 Dec 2014 00:00:00 GMTDr. Bruno García will sail around the world with VHIR's logo on his boat (22/12/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=275&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0275\2014_0275_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> His name is Bruno García, Doctor Bruno García, cardiologist and member of the research groups on Cardiovascular diseases, and amateur sailor. In not much more than a week he will part to go around the world on a boat with his brother, Willy, as they are one of the 8 teams that participate on the Barcelona World Race (BWR) that starts in Barcelona on the 31st of December. He is 47 years old and this will be his second BWR. His brother is a jeweler and is 42. They are both going to share three months or more, depending on if they make it to the end, a sports and human adventure on the boat ‘We are water’, the name of the foundation that provides logistic support in this participation. But Bruno has wanted to add one more brand to his boat, the logo of the Vall d’Hebron Institute of Research (VHIR), to raise awareness among those who follow the regatta during the following months about the importance of research in cardiovascular diseases, especially in congenital heart diseases and the ones that affect children. “Combining my adventure with the VHIR will help spread the message of the importance of congenital heart diseases, of cardiovascular pediatric problems and, in general, of all research in the heart area”, points out Bruno as he presents his boat to the media, as well as his reasons to enter this adventure, together with the synchronized swimming Olympic team, that has sponsored the ‘We are water’. “We are water and the VHIR are two messages totally in line with solidarity and awareness”, says Dr. García while holding a catheter in his hand showing it to the cameras as a symbol of uniting profession and vocation. His little brother observes him while they both answer questions about how the cohabitation will be in the next three months, while sailing the 23 thousand nautical miles of the race, non-stop. It is going to be worth it and from the VHIR we will follow their journey. And remember, if Bruno is capable of sailing around the world to raise awareness to people, everyone can help on their own way to research, in this case at VHIR, through the donations web page yoinvestigo.org. </td></tr></table>comunica@vhir.org (VHIR)Mon, 22 Dec 2014 00:00:00 GMTVHIR wishes you Season's Greetings and a Happy New Year (19/12/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=271&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0271\2014_0271_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Vall d’Hebron Institute of Research (VHIR) sends Season’s Greetings through the institute’s new mascot, The VHIR, who will help the center to spread its research to the society more easily. The mascot has switched to Christmas mood to wish everyone Seasons's Greetings and a Happy New Year 2015. VHIR, the mascot, that was presented for the first time during the celebration of the 20th anniversary of the institute and, from 2015 will be the image of the outreach activities of the institution. The mascot VHIR and this card are a common project between La Casa de Carlota and Vall d’Hebron Institute of Research. La Casa de Carlota is a design studio composed by disabled designers and young design students, who work to unite talent, normalize and integrate into the labor market every individual’s unique capacities and not their disabilities.  Merry Christmas and a Happy New Year from VHIR </td></tr></table>comunica@vhir.org (VHIR)Fri, 19 Dec 2014 00:00:00 GMTVHIR and Interarts present the results of a Project to ensure sexual and reproductive rights of immigrant population in Spain (19/12/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=272&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0272\2014_0272_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Researchers from Vall d’Hebron Research Institut (VHIR) and the Programa de Salut Internacional de l’Institut Català de la Salut (PROSICS) along with Interarts, presented the results of the “Diagnosis of the access situation to sexual and reproductive rights (SRR) of migrant women of fertile age in Spain”, in the frameworks of the project DECIDES ESPAÑA. The aim of this initiative is to improve equity in access to and exercise of sexual and reproductive rights of young and women of migrant origin in Spain. During the presentation, Gemma Garreta, member of VHIR-PROSICS, exposed the main conclusions of the study: the need to involve men in issues of sexual and reproductive health, and not only women; the advisability of providing tools to health professionals to allow them to create a relation of empathy and trust with migrant women patients and the need to develop formative and outreach materials about sexual and reproductive health that integrate an equity point of view. In this regard, Jordi Gómez, doctor responsible of the Unit of tropical and international health at Vall d’Hebron, explained that “the study we carried out suggests that social determinants of migrant women are a key to understand their access to the health system regarding sexual and reproductive health”. This, according to Gómez, guides the development of the project, which works “improving the attention provided by healthcare professionals through training, as well as, in a second phase, raising awareness of population”. After presenting the results, the meeting closed with a round table conference, moderated by Hakima Ouaarab, from PROSICS-Vall d’Hebron. This project is co-funded by the Financial Mechanism of the European Economic Area (EEA Grants) which aims at contributing to the reduction of economic and social inequalities, and strengthening links between donor (Iceland, Liechtenstein and Norway) and beneficiary countries (17 EU Member States). The Plataforma de ONG de Acción Social is the Operational Unit of the Programa de Ciudadanía Activa<span style=" font-size: 8pt; font-fam</td></tr></table>comunica@vhir.org (VHIR)Fri, 19 Dec 2014 00:00:00 GMTThe Spanish Parkinson Federation recognizes a study by Dr. Vila as the best research paper (18/12/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=267&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0267\2014_0267_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Dr. Miquel Vila, head of the Neurodegenerative Diseases Group of the VHIR, and member of CIBERNED, has been recognized as the best research paper in the VII edition of the Spanish Parkinson Federation (FEP) awards. The jury recognized the article ‘Lewy Body Extracts from Parkinson Disease Brains Trigger a-Synuclein Pathology and Neurodegeneration in Mice and Monkeys’, published last march in the scientific journal Annals of Neurology and presented by Dr. Miquel Vila, among the 21 articles presented coming from research centers and hospitals from all over Spain. The same scientific journal, Annals of Neurology, and its editorial board had already awarded Dr. Vila’s article two months ago, as best article of 2014. The study shows that pathological forms of the alfa-synuclein protein present in the brain of deceased Parkinson Disease (PD) patients were capable of initiating a PD-like pathological process in mice and primates. For the authors, these findings provide new information on how the disease is initiated and amplified. For Dr. Gurutz Linazasoro, president of the FEP jury, “the work can explain the mechanism of neuronal degeneration and the progression of the symptoms. The most direct potential consequence is the identification of new targets for neuroprotective therapies”. Moreover, he assures that “we have to stress that the work is fruit of the collaboration effort of different groups, national and international, and makes an example of the way of making big science in the 21st century”. </td></tr></table>comunica@vhir.org (VHIR)Thu, 18 Dec 2014 00:00:00 GMTKilometric donations (17/12/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=266&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0266\2014_0266_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Recovering from an IronMan competition can be a challenge by itself but for Chronic Fatigue Syndrome (CFS) patients the real challenge is every day life. The consequences of participating in one of the most physically demanding races are very similar to the symptoms that CFS patients experiment. This illness affects up to 3% of the population. With this idea in mind, 8 participants from the IronMan race in Barcelona have started the #IMHeart project. Using a Smartphone app kilometers will be accumulated whenever the users are exercising, later those kilometers generated will be ‘donated’ to CFS research projects. The kilometers covered will be given to the study coordinated by Dr. Jesús Castro, from the Chronic Fatigue group at VHIR, headed by Dr. José Alegre, titled “CFS and fibromyalgia in teens: emergent entities that determine academic failure and deterioration of life quality”. The project is drove in collaboration with several national and international research and university centers such as Hospital Sant Joan de Déu, Centro Médico Delfos, Hospital Clínic and University of Bristol (UK). The ‘Associació Catalana d’Afectats de Fibromialgia, SFC I SQM’ (ACAF) also gives support to the cause. For participating in the donation it is necessary to get registered in the web: http://app.iwopi.org/login, and download the Runkeeper app for Smartphone. Once some distance is covered, you can donate the kilometers through the iWOPI web to the CFS project. Through the iWOPI platform, the kilometers given by the donors will be accumulated. The challenge thrown is to achieve 150.000 km in three months. Those kilometers (or miles) can be earned either running, walking, swimming or riding a bike. The ultimate objective is to be on the move for those who cannot do it every day. </td></tr></table>comunica@vhir.org (VHIR)Wed, 17 Dec 2014 00:00:00 GMTAmics de Les Arts raise more 40,000 euros for child cancer research (15/12/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=263&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0263\2014_0263_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Catalan band ‘Els amics de les Arts’ has raised 40 thousand Euros in two benefit concerts organized by Albert Bosch Foundation in order to contribute to child cancer research in Vall d’Hebron Institute of Research (VHIR), group headed by Dr. Sánchez de Toledo. The group threw its second and last benefit concert last Thursday in Sant Cugat’s Teatre-Auditori. They also had some friends joining them on stage, such as Joan Dausà, Roger Mas, Cybee, Els Catarres, Blaumut and Mamzelles. Els amics de les Arts have thanked trough their web the unselfish collaboration they have received saying “all the work that means organizing this kind of concert pays off when you find yourself on stage singing someone else’s song that you love, or when you hear one of your songs but with a voice that’s not your own, or when your fingers are literally trembling accompanying someone who has written songs that are very important for you”. VHIR’s researchers were invited by the band to this second concert which was full of emotion and complicity between the band and the invited musicians. The first benefit concert was in Olot, at Braus Square, where the band presented its new album ‘Només d’entrar hi ha sempre el dinosaure’. All the money raised during the concerts will go to the three research lines of VHIR’s Translational Research in Child Cancer Group, with whom Foundation A. Bosch is collaborating in order to get better diagnosis and therapies. Foundation A. Bosch was created in 2004 by Noel Alimentària, with the aim of promoting medical research for child diseases and lupus. </td></tr></table>comunica@vhir.org (VHIR)Mon, 15 Dec 2014 00:00:00 GMTThe editor-in-Chief of 'The Lancet' closes Vall d'Hebron 18th Annual Conference (12/12/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=262&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0262\2014_0262_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The editor-in-Chief of the prestigious scientific journal The Lancet, Dr. Richard Horton, has come to Vall d’Hebron to give the closing speech of the Vall d’Hebron Universitary Hospital 18th Annual Conference which ended this Friday, December 12th. With an enthusiastic speech with references to Picasso and Salvador Espriu, Horton has reflected on the challenges of the future, that in his opinion are global vision of health, science, society, solidarity and sustainability. The conference has ended the 8th VHIR Scientific Conference. Before the The Lancet’s editor conference, VHIR’s director, Dr. Joan Comella, has presented the Institute’s annual results. He has highlighted the good results on scientific production that puts VHIR’s researchers in first-line research, with an accumulated impact factor during 2014 of 3.500. He has also presented the great economic results of the centre, obtained thanks to competitive calls, clinical trials, agreements with industry and donations. The hospital’s manager, Dr. José J. Navas, has praised the daily work carried out by VHIR’s researchers to improve people’s health and life quality, and has remarked the importance of innovation to speed up this goal. VHIR grants Once again, the Institute has awarded the predoctoral grants during the Annual Conference, but for the first time in this 18th edition, ‘VHIR’s friends’ have participated in the ceremony. The Institute’s donors will fund for 3 years the predoctoral training of Casandra Riera, researcher from the Bioinformatic Group, and Luz Jubierre<span style=" font-size: 8pt</td></tr></table>comunica@vhir.org (VHIR)Fri, 12 Dec 2014 00:00:00 GMTOpening of the VHIR's 8th Scientific Conference (11/12/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=261&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0261\2014_0261_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Today has started the 8th VHIR’s Scientific Conference. During two days, 41 physicians in training, 36 predoctoral researchers, 9 postdoctoral researchers and 9 researchers in nursing will present what they are currently investigating at Vall d’Hebron Institute of Research (VHIR). On this edition the sessions will take place in different places: the Auditorium of the 10th floor of the hospital will host the first part of the predoctoral sessions and all the nursing presentations; the second part of the predoc sessions will take place at the conference room of the Collserola building; the conference room of the ground floor of the hospital will host the presentations of the physicians in training; and the auditorium of the Pavelló Docent building will host the presentations of the postdoctoral researchers. The best presentations will be awarded at the 18th Annual Conference, that will take place on Friday at the Pavelló Docent. On the ceremony, will be also recognized the winners of the VHIR predoctoral grants, the ‘VHIR friends’ predoctoral grants, and the post-mir grant by the Obra Social ‘la Caixa’. The annual lecture will be pronounced by the editor-in-chief of the prestigious scientific journal The Lancet, Dr. Richard Horton. The title of his speech is “Science and charity: reflections on the purpose of medicine and the meaning of health”. - Program of the 8th VHIR Scientific Session <p style=" text-align: left; text-indent: 0px; padding:</td></tr></table>comunica@vhir.org (VHIR)Thu, 11 Dec 2014 00:00:00 GMTWorld experts in endoscopic surgery meet in Vall d'Hebron (10/12/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=260&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0260\2014_0260_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The World Institute for Digestive Endoscopy Research (WIDER-BCN) from Hospital Universitary Vall d’Hebron has organized a two day International Course: Natural Orifice Translumenal Endoscopy Surgery (NOTES) dedicated to transluminal endoscopy trough natural orifices. Over 130 doctors, surgeons and researchers from all over the globe participated in this 8th edition, directed by WIDER’s leader, Dr. José Ramón Armengol, and Doctors Manuel Armengol and Antonio J. Torres García. The meeting has become the world’s most outstanding forum about advanced endoscopic and transluminal surgery. WIDER center was created in 2008, as an agreement between Generalitat de Catalunya, Obra Social “la Caixa”, Vall d’Hebron Universitary Hospital and VHIR to encourage and promote research in endoscopic surgery and implement a specific and autonomous program inside VHIR’s structure for this area. Specifically, research in endoscopic and surgery technology, experimental endoscopic research using NOTES methodology, clinical innovation research and training in medical-surgical digestive endoscopy in the different specialties. WIDER institute, which is led by Dr. José Ramon Armengol, aims to clinical application, animal experimentation and national and international diffusion of their activities. One of these activities is the NOTES Course that in its 8th edition offered presentations about simulations such as Single port access, NOTES experimental, NOTES clinic, NOTES applied to obesity and transrenal surgery. In endoluminal endoscopy new diagnostic alternatives were presented in bilipancreatic diseases, and in endomulnial therapeutic specialty Poem’s new techniques with Acalasia treatment and new techniques in tumor resection. In this edition two surgeries were broadcasted, one of them from the clinical side, endoscopy, Acalasia patients and tumoral and polypoid deformation of the digestive tract. The other video was broadcasted from VHIR’s ‘Animal Facility’, very sophisticated bile and pancreatic drainage interventions using ecoendoscopy. All the patients who were operated have evolved without complications and were sent home (4 acalaseis, 6 resections and sewing of the gastric and colonic wounds). The course’s first night a dinner-symposium was thrown in CosmoCaixa, presided by the Health Consellery representative, Joaquim Casanova, and La Caixa’s representative, Enric Banda. In this event two endoscopy experts, Kiyokazu Nakajima and Sergey Kantsevoy, spoke about non-sedated colonoscopy and automatic use of CO2 in endoluminal surgery and esdoscopy. </td></tr></table>comunica@vhir.org (VHIR)Wed, 10 Dec 2014 00:00:00 GMTThe Chronic Fatigue group presents the results of a clinical trial and a biological study with antioxidants (09/12/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=259&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0259\2014_0259_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Chronic Fatigue group at Vall d’Hebron Institute of Research (VHIR), led by Dr. José Alegre, presented together with the Catalan company VITAE the preliminary results of a clinical trial and a biological study with Reconnect®, based on the combination of antioxidants Coenzyme Q10 + NADH, with the aim of improving the symptoms of the Chronic Fatigue Syndrome (CFS).  The clinical trial has demonstrated that the synergetic combination of both natural antioxidants improves the symptoms of the disease and also recovery of biomarker parameters. VHIR researchers conducted the Phase II, double blinded and randomized clinical trial, in 73 patients diagnosed with chronic fatigue syndrome at Vall d’Hebron University Hospital. During 8 weeks, half of them were given CoQ10 + NADH and the other half, placebo, in order to compare the effect of the drug on the cardiac adaptations of patients with chronic fatigue. Furthermore, researchers also measured the intensity of fatigue, pain and sleep problems, before and after the treatment. The results have been recently published in the journal Antioxidants &amp; Redox Signaling. Dr. Jesús Castro, principal investigator of the Chronic Fatigue group, highlights five benefits of the study: “patients who received this combination of antioxidants showed a significant fatigue reduction, an increase in antioxidant levels and recovery of energy and mitochondrial function in ATP form, an increase of synthase citrate enzyme and a reduction in oxidized lipids; all of them key factors that can contribute to the illness symptomatology”. The next step for VHIR’s researchers and VITAE Co. will be to increase to 300 CFS patients more enrolled in the clinical trial from the Chronic Fatigue Clinical Unit at the Vall d’Hebron Hospital. </td></tr></table>comunica@vhir.org (VHIR)Tue, 9 Dec 2014 00:00:00 GMTThe loss of the gene RHOA contributes to the progression of colorectal tumors and metastasis (05/12/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=258&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0258\2014_0258_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Researchers of the Oncology Molecular group from CIBBIM- Nanomedicine at Vall d’Hebron Institute of Research (VHIR) have discovered that the loss of a gene, called RHOA, enhances tumor progression and metastasis in colon and rectal cancer. The study also reveals the mechanism of action of this gene, whose role is completely different in other types of cancer. The results have been published in Nature Communications. The main author of the study, Dr. Diego Arango, has studied the role of RHOA since 2005, when he discovered with another international research group that it was one of the genes that presented more differences in its expression between patients with good and poor prognosis. Based on this first study, the aim of the research that now has been published, was to determinate whether the loss of RHOA levels is the cause (or one of the causes) of the poor prognosis of the patients. In order to prove it, researchers inactivated RHOA in the gut of mice that had started the tumorogenesis, which is the process by which cancer is produced. “We discovered that the animals died earlier and had more and bigger tumors”, explained Dr. Arango, head of the Oncology Molecular group, and researcher of the CIBER of Bioengineer, Biomaterials and Nanomedicine. To confirm the results, they also developed in vitro techniques, which proved that the loss of RHOA is associated to major tumor proliferation and cellular differentiation. After discovering RHOA’s function in colorectal cancer tumors, VHIR’s team sought to determine if the gene’s absence also had a similar effect in metastasis. Using a murine study, the researchers detected that RHOA’s inactivation made colon cancer cells more metastatic. According to the researcher, that explains why “in the metastasis samples from patients with colorectal cancer we have found less RHOA expression than in the primary tumors”.&nbsp; </td></tr></table>comunica@vhir.org (VHIR)Fri, 5 Dec 2014 00:00:00 GMTVall d'Hebron's Market and VHIR promote a solidary calendar (04/12/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=257&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0257\2014_0257_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Vall d’Hebron Market has edited a solidary 2015 calendar, and the money collected will be used in heart disease research in Vall d’Hebron Institut de Recerca (VHIR). The calendar costs one euro, and can be bought in any of the market stands. With this action the market workers wanted to do their bit in heart diseases research, as it causes thousands of deaths every year. Overall, there have been produced 2.000 calendars, drown by Mario Tarragó and designed by Jordi Santamaria. Dr. David García Dorado is head of the Cardiovascular Diseases group at VHIR, and works in prevention, diagnosis and treatment of the heart diseases. The researchers also coordinate actions in sanitary education, healthy lifestyle promotion and create new diagnosis and therapeutic tools and new care systems. </td></tr></table>comunica@vhir.org (VHIR)Thu, 4 Dec 2014 00:00:00 GMTBarcelona's Medical Board acknowledges Vall d'Hebron professionals (03/12/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=256&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0256\2014_0256_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Barcelona’s Medical Board has awarded five Vall d’Hebron professionals with its 2014 Professional Excellence Award: Dr. Fernando Azpiroz, head of the Physiology and Pathophysiology of the Digestive Tract Group of the Vall d’Hebron Institut de Recerca (VHIR), Dr. Francesc Bosch, head of VHIR’s Experimental Hematology Group, Dr. Josep Àngel Bosch, Internal Medecine expert, and member of the Systemic Diseases Group, Dr. Manuel Matas, specialist in Angilology and Vascular and General surgery, and Dr. Marius Morlans, retired Nephrology specialist. The professional association has also recognized the work carried out by the Cardiology Unit in Vall d’Hebron’s Universitary Hospital, headed by Dr. David García Dorado, head of VHIR’s Cardiovascular Diseases Group. Two of VHIR’s group heads have been awarded Dr. Fernando Azpiroz graduated in Medicine and Surgery in 1977, from Universidad de Valladolid. 9 years later he got his PhD from Universidad Complutense de Madrid, and in 2011 he was appointed Professor in Medicine by the Science and Education Ministry. His first experience in Vall d’Hebron was in 1986, as an associated researcher at the Digestive Tract Research Unit. Before he had been doing his residence in Hospital Clínico San Carlos in Madrid, and had also worked for three years as a researcher in Mayo Clinic at Rochester, Minnesota. Nowadays he leads the hospital’s Digestive Unit, and also VHIR’s research group, composed by over 25 professionals. They are doing first line research in fields such as: abdominal distension, microbiota, or irritable bowel syndrome, among others.&nbsp; Dr. Francesc Bosch graduated in Medicine and Surgery from Universitat de Barcelona in 1988. After finishing his residence in Hematology at Barcelona’s Hospital Clínic, he got his PhD in 1997 also from Universitat de Barcelona. His studies about cyclin D1 overexposure in lymphoproliferative syndromes lead him to take a 2 year postdoctoral position at Columbia University, New York. He returned to Barcelona in the year 2000, and 9 years later he was announced Head of the hemathology Unit of Vall d’Hebron, and Head of the Experimental Hematology research Group. The group is formed by over 20 professionals, and leads three research lines: chronic lymphatic leukemia, lymphoproliferative syndromes and myelodysplastic syndromes. </td></tr></table>comunica@vhir.org (VHIR)Wed, 3 Dec 2014 00:00:00 GMT'Wounded memories, rebel bodies' arrives to Terrassa delivered by Dr. Josep Gámez (02/12/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=255&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0255\2014_0255_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Dr. Josep Gámez, head of Vall d’Hebron Institut de Recerca (VHIR) Peripheral Nervous System group, made the inaugural speech of the exhibition ‘Wounded memories, rebel bodies: itineraries against oblivion’. Until December 4th, exhibition room Cima of the patronal Cecot building will hold this exhibition that has toured Spain, showing the nude bodies of people who suffered the disease. The VHIR researcher spoke about the need to establish a comprehensive care system to help these people, who now, decades after overcoming the disease, deal with what is known as post-Polio Syndrome. Nowadays professionals in Vall d’Hebron look after over 200 people with this illness. The photographic exhibition, with images by Bernat Millet, explores poliomyelitis’s memory through the bodies of people who went through the illness, its consequences, and further effects. The exposure’s goal is to raise awareness in society about the illness trough the scars and stories of the people pictured. </td></tr></table>comunica@vhir.org (VHIR)Tue, 2 Dec 2014 00:00:00 GMTVHIR signs an agreement with the Universidad Técnica de Ambato (02/12/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=251&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0251\2014_0251_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Vall d’Hebron Institute of Research (VHIR) has signed an alliance with the Universidad Técnica de Ambato, in Ecuador, to promote the exchange of professors and students, organize training activities, and aid in the execution of common research projects. Dr. Juan Ángel Recio, head of the VHIR Melanoma Group, and Mileydis Perez, researcher of the same group, will be in charge of monitoring the activities and common projects between the two centers. As a first project, researchers of both centers will study the role in metabolism of the enzymatic complex aldehyde dehydrogenase (ALDH) and the resistance to therapeutic treatments of the tumor stem cells. This research, that will last 3 years, aims to determinate the biomolecular function of the ALDH isoforms in the control of the cellular death of the tumor stem cells in lung cancer and identifying new targets for the treatment of the illness. </td></tr></table>comunica@vhir.org (VHIR)Tue, 2 Dec 2014 00:00:00 GMTVHIR and Interarts begin a project to ensure sexual and reproductive rights of immigrant population in Spain (30/11/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=253&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0253\2014_0253_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Researchers from Vall d’Hebron Research Institut (VHIR) and the Programa de Salut Internacional de l’Institut Català de la Salut (PROSICS) along with Interarts, presented the project DECIDES ESPAÑA. The aim of this initiative is to improve equity in access to and exercise of sexual and reproductive rights of young and women of migrant origin in Spain. Until October 2015, the experts involved in the project will develop the following activities: an assessment on equity in access to Sexual and Reproductive Health services, whose results will be published on December 18th&nbsp; at the Vall d'Hebron infrastructure; educational materials that will strengthen the cultural competencies of health sector professionals as well as of key actors in this field; 10 training workshops on the use of the educational material by professionals from the health sector; 5 awareness-raising activities geared towards civil society on sexual and reproductive rights and equality in a context of cultural diversity; 8 presentations on the subject&nbsp; in a context of cultural diversity and equality; as well as 1 workshop of audiovisual creation and reflection on this field for young immigrants. The&nbsp; group of professionals on Infectious Diseases from VHIR and PROSICS have over 20 years of extensive experience in the field of intercultural medicine, both at local / national and international level. The project was presented on November 19th at Casa del Mar in Barcelona, at the conference entitled "Women Sexual and Reproductive Rights. A transnational vision of Female Genital Mutilation". DECIDES ESPAÑA is co-funded by the Financial Mechanism of the European Economic Area (EEA Grants) which aims at contributing to the reduction of economic and social inequalities, and to strengthening the relationships between donor states (Iceland, Liechtenstein and Norway) and beneficiary states (17 EU Member States). The Plataforma de ONG de Acción Social is the Operatoring Agency of the Programa de Ciudadanía Activa (Active Citizenship Programme) which is endowed with EUR 4.6 million for the strengthening of NGOs and their contribution to social justice and sustainable development. Follow the Ciudadanía Activa program on Twitter and Facebook. </td></tr></table>comunica@vhir.org (VHIR)Sun, 30 Nov 2014 00:00:00 GMTVHIR and the Innovative Medicine Initiative present the future call for proposals (28/11/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=252&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0252\2014_0252_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> On the 26th of November, Vall d’Hebron Institute of Research (VHIR), together with the Innovative Medicine Initiative (IMI) held an Infoday. The main objective of this event was to show more in the details all the future call for proposals of the Public Private Partnership. To start with, Dr. Thomas Eichholtz, CSO and Corporate Director of R&amp;D at Almirall, presented the dynamics behind EFPIA and the call for proposals). He was followed by Dr.Eva Molero, CEO at Synapse Research Management Partners, who gave the partipants more details about real IMI projects, and keys to successful participation and management of such projects. Dr. Marta Gomez Quintanilla, Spanish representative in IMI 2 from CDTI, showed the Spanish participation in IMI so far, and also insisted on the need to be more proactive, and participate more actively in future calls and projects. After the coffee break, Dr. Magda Gunn, from the IMI executive office, explained very clearly the rules and framework of IMI 2, giving tips on the dos and donts in the application process. Participants from different research institutes could discuss and exchange over the lunch break. Then, more insight on the future topics to come were given by Dr. Magda Gunn (IMI) together with Dr. Nima Behkami, Strategic Alliance director at MSD. Dr. Farid Bidgoli, MSD Real World Evidence Manager, also gave a bit more detail on the work they are currently carrying on. Finally, a specific session on venture capital closed the day. Dr. Rémi Droller, Managing partner at Kurma Partners, together with Dr. Nima Behkami led toward a discussion on the potential of future businesses supported by VC in the biomedical field. </td></tr></table>comunica@vhir.org (VHIR)Fri, 28 Nov 2014 00:00:00 GMTThe Spanish version of the Gut Microbiota Worldwatch web has been released (28/11/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=250&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0250\2014_0250_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The ‘Gut Microbiota &amp; Health Section’ of the European Society Neurogastroenterology and Motility (ESNM), has released the Spanish version of the Gut Microbiota Worldwatch web. The web’s aim is to bring closer the importance for health and life quality of the gut microbiota (or intestinal bacteria) to the society and the media, and of course, to expand the knowledge about the issue. The Gut Microbiota Worldwatch’s President is Dr. Fernando Azpiroz, head of the Physiology and Pathophysiology of the Digestive Tract group at Vall d’Hebron Institute of Research (VHIR), and also head of the ESNM Gut Microbiota &amp; Health section, member of the UEG-United European Gastroenterology. Dr. Azpiroz emphasizes that “it is important for people to know the activity of the universe of bacteria they host in their guts and its key role for many physiological functions that our body is not capable of doing by itself, as some fiber digestion or some vitamin production, among others”. He also assures that if we care about our intestinal microbiota “it will take care of us, helping us protect our health and life quality”. Secondly, Dr. Francisco Guarner, researcher of the same group in VHIR, is a member of the experts’ board, contributing with his knowledge in the fields of intestinal mucosa, inflammatory bowel disease and probiotics, among others. He is the leader of the MetaHit Project in Spain whose goal is to associate bacterial genes with human health and diseases. The web is a powerful and extensive source for gut microbiota information online, with content selected from this experts’ platform and adapted for easier accessibility for a non-scientific audience. The content can also be found on their Twitter and Facebook accounts. </td></tr></table>comunica@vhir.org (VHIR)Fri, 28 Nov 2014 00:00:00 GMTThe College of Nursing of Barcelona has granted two projects of the Health Care research group (27/11/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=243&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0243\2014_0243_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The College of Nursing of Barcelona has granted two out of the nine aids of research to two predoctoral researchers of the Health Care research group, led by Dr. Carmen Fuentelsaz at Vall d’Hebron Institute of Research (VHIR). The nurse Esperanza Zuriguel leads the first project entitled “Evaluation of the critical thinking among nursing professionals, according to the Alfaro-LeFevre circular model”. The aim of her research, funded with 7,260 euros, is to elaborate a test to assess the critical thinking of the nursing staff, and to analyze its validity and reliability. The second project, called “Therapeutic adherence in adolescents, exploring opinions and experiences”, is led by the nurse Maria Luisa Cebrián and has been endowed with 2,601 euros. The objective of her study is to know the everyday experiences of adolescents who have underwent renal transplant, have diabetes or cystic fibrosis. She will also gather information about the vision of the young people concerning the medical and family attention received, as well as their proposals for improvement. </td></tr></table>comunica@vhir.org (VHIR)Thu, 27 Nov 2014 00:00:00 GMTVall d'Hebron hosted an international symposium of neuromonitoring and neurocritical patients (25/11/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=242&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0242\2014_0242_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Neurotraumatology and Neurosurgery Unit (UNINN) at Vall d’Hebron Institute of Research (VHIR) organized the XVI International Symposium on Neuromonitoring and Neurocritical Patients, which took place in Barcelona from the 18 to the 22 of November. During 5 days, the Altimara Hotel was the meeting point of more than 450 multidisciplinary professionals in the diagnosis and treatment of neurocritical patients and those with traumatic brain injury. The opening lecture of the symposium was carried out by Dr. Douglas H. Smith, Director of the Penn Center for Brain Injury and Repair of the Pennsylvania University. He talked about diffuse axonal damage after traumatic brain injury. The congress also included the XI Course on nursing care in neurocritical patients, accredited by the Consell Català de Formació Continuada de les Professions Sanitàries. </td></tr></table>comunica@vhir.org (VHIR)Tue, 25 Nov 2014 00:00:00 GMTResearchers identify a gene associated with susceptibility to cervical artery dissection (24/11/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=240&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0240\2014_0240_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Researchers from the International Stroke Genetics Consortium, in which participate Dr. Joan Montaner and Dr. Israel Fernández Cadenas from the Neurovascular Diseases group at Vall d’Hebron Institute of Research (VHIR), have discovered the association of a gene, called PHACTR1, with the risk of suffering cervical artery dissection. The results have been published in Nature Genetics. European and American researchers screened the entire genome of 1,400 patients with cervical artery dissection, some of them treated at Vall d’Hebron, and 14,000 referents without this disease. The aim of the study was to identify genes predisposing to this disease in order to better understand its mechanisms and improve prevention strategies. Thanks to this in-depth analysis, which is the largest carried out ever, Dr. Israel Fernández Cadenas, researchers from VHIR and the Fundació de la Docència i Recerca MutuaTerrassa, assures that they have discovered that “individuals carrying a certain genetic variant in the PHACTR1 gene are more likely to suffer this disease that represents one of the main causes of stroke among young people”. In a previous study in which also participated VHIR researchers, this genetic variant had already been associated with people with higher risk of suffering migraine. It was known that migraine was a risk factor to suffer cervical artery dissection, but there was not any biological connection between these two diseases. Cervical artery dissection is caused by a tear in a brain supplying artery wall (carotid or vertebral) that can lead to compression of adjacent nerves and to blood clotting within the artery, potentially causing occlusion of downstream vessels and brain infarction. Despite its low prevalence –it affects 2,6 out of 100,000 people, it has serious effects in the health of the survivors. According to Dr. Joan Montaner, “understanding the mechanisms by which this region of the genome appears to influence key vascular fun</td></tr></table>comunica@vhir.org (VHIR)Mon, 24 Nov 2014 00:00:00 GMTVHIR celebrates 20 years of excellence in research (21/11/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=238&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0238\2014_0238_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Vall d’Hebron Institute of Research (VHIR) celebrated its 20th anniversary with an academic event that took place on Friday at the Pavelló Docent building, in front of over 200 people who are part of its history. On Thursday evening, promoters and authorities that participated in VHIR’s foundation, as well as donors, private companies who support the Instititute and technological partners, participated in an institutional dinner at Cosmocaixa. In both events, VHIR presented a video of its history. The academic event paid tribute to the key researchers in the foundation of the Institute: Dr. Simó Schwartz, HUVH’s first Research Director, Dr. Jordi Soler i Soler, former head of the Cardiology Service, Dr. Joan Ramon Malagelada, former head of the Gastroenterology Service, Dr. Jaume Guàrdia, former head of the Liver Diseases Group, and Dr. Àngel Ballabriga (1920-2008), former Director of the Children’s Hospital. Special mention was also given to people who have contributed to the center’s management during the past 20 years. This would be the case of former directors, –Dr. Carles Miquel, Dr. David García Dorado, Dr. José María Sáez as a posthumous title, and Dr. Juan Emilio Feliu– Trustees’ presidents or vice-presidents –Marina Geli, Dr. José Luis Sancho, and Dr. Jaume Raventós– and presidents of the Scientific Internal Committee that still are connected to VHIR –<span style=</td></tr></table>comunica@vhir.org (VHIR)Fri, 21 Nov 2014 00:00:00 GMTMutual Médica grants a study conducted by Dr. Marc Ramentol (19/11/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=241&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0241\2014_0241_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Dr. Marc Ramentol, researcher from the Systemic Diseases group at Vall d’Hebron Institute of Research (VHIR), has been granted with the Mutual Médica 2014 call, endowed with 4,000 euros, to investigate whether the persistent symptoms in the remission phase of Churg-Strauss syndrome are caused by an autoimmune expression of the disease. In the ceremony award, VHIR researcher highlighted the “rigorousness and the impartiality of the jury in the selection of the projects submitted, which means a great reputation for the young researchers awarded”. The eosinophilic granulomatosis with polyangiitis or Churg-Strauss syndrome is a systemic rare disease, with a prevalence of 2-6 cases out of one million people, which usually appears in patients who had previously suffered allergic asthma. </td></tr></table>comunica@vhir.org (VHIR)Wed, 19 Nov 2014 00:00:00 GMTVHIR's biobank at a doctor's click (19/11/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=237&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0237\2014_0237_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The biobank from the Vall d’Hebron University Hospital has implemented a new system in order to ease and speed up the reception of blood and urine samples extracted at the hospital in order to use them in research. This new proceeding, which is integrated in the hospital’s circuit, makes easier for the doctor to ask for a Biobank analysis of a sample, as it’s only one click away, and always with the patients consent. Thanks to this new system, the samples will arrive correctly labeled and work will be easier for the researchers, who were the ones in charge of asking the medical staff to extract and send the samples for their studies. The Cardiocirculatory Pathology group, headed by Dr. David García-Dorado, is already taking profit of this system. Actually, the Cardiology Bank of the Biobank is integrated within  healthcare and research activity from the Cardiology service and is a key piece of the PRECISED project; an integrated excellence project from Instituto de Salud Carlos III, in which eight VHIR groups work to prevent isquemic cardiovascular accidents in diabetic patients. For Dr. García-Dorado, the start of the Cardiology Bank “opens new horizons for cardiovascular research in the molecular medicine era, which is a remarkable landmark in our group’s history”. </td></tr></table>comunica@vhir.org (VHIR)Wed, 19 Nov 2014 00:00:00 GMTThe Health Care research group receives the prize to the best oral communication in the 18th International Nursing Research Conference (18/11/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=239&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0239\2014_0239_IMATGE.JPG" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Health Care group research group, led by Dr. Carmen Fuentelsaz, has been awarded the best oral communication in the 18th International Nursing Research Conference, held in Vitoria-Gasteiz. The award-winning work, “Blood extractions in critical patients as a cause of&nbsp; anemization”, is the fruit of six years of work at VHIR under the supervision of Anabel Solsona, Maria del Mar Eseverri, Mercedes Garrido, Maria Alba Riera, Jordi Gómez, Montserrat Lolo, Maria Agustina Paricio, Dina Butrón and Elisabeth Gallart. The Conference, organized by the Health Care research unit at the Instituto de Salud Carlos III, is the most important meeting in health care research taking place in Spain. In the present edition 433 research projects were presented, almost all of them developed by nursing professionals from 23 different countries, amongst which Catalunya stands out as the one that presented more projects, with a total of 77. </td></tr></table>comunica@vhir.org (VHIR)Tue, 18 Nov 2014 00:00:00 GMTSOM Biotech and the Vall d'Hebron Hospital have initiated a clinical trial in patients using a new repositioned drug for amyloidosis (18/11/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=235&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0235\2014_0235_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> SOM Biotech, located at the Parc Científic de Barcelona, has initiated the clinical phase of an innovative oral therapy for transthyretin amyloidosis (ATTR): compound SOM0226, a reprofiled drug developed entirely by the biopharmaceutical company. The phase IIa proof-of-concept trial in humans is being conducted at the Vall d'Hebron University Hospital, coordinated by Dr. Josep Gámez from the Peripheral Nervous System research group, and the treatment has already been administered to the first patients. The hospital will assume, jointly with the biotech, the risks and return on investment of the development of the drug, with the recent support from the Spanish Ministry of Economy. Transthyretin amyloidosis is a rare disabling disease with a severe prognosis that primarily affects the peripheral nervous system and the heart and, in some cases, is inherited from parents to children. The disease develops when the liver and other parts of the body produce the mutated protein transthyretin (TTR), causing a number of aggregates that are deposited into multiple organs. This excessive accumulation of protein, known as amyloid deposits,causes local cell damage that presents with a variety of clinical symptoms. These symptoms include severe cardiac and neurological problems that lead to the death of the patient within a period of 5 to 15 years. “Currently there is no other drug undergoing marketing approval for transthyretin amyloidosis in Europe. The only treatment available is a drug discovered in the United States (with the exorbitant price of more than 140,000 € per patient and per year) and liver transplantation, suitable only for a particular population group and with very high social and health costs", says Dr. Raúl Insa, founder and CEO of SOM Biotech. SOM0226 is a potent inhibitor of the amyloidogenic process with an innovative dual mechanism of action: as stabilizer of the transthyretin protein and disruptor of the fibers once they are deposited into the tissues. To cut it short, it stops progression and reverts the disease. This drug may also be effective against the 4 variants of transthyretin amyloidosis - polyneuropathic, cardiac, senile systemic and the CNS selective - including the more advanced stages of the disease. As a consequence, "this new therapeutic alternative will not only be able to confront Transthyretin amyloidosis but will also be able to prevent its progression, avoiding the formation of amyloid fibers”, remarks Dr. Gámez. </td></tr></table>comunica@vhir.org (VHIR)Tue, 18 Nov 2014 00:00:00 GMTVall d'Hebron researchers participate in the annual meeting of the REIPI (18/11/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=236&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0236\2014_0236_IMATGE.bmp" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Researchers from the groups of infectious diseases and microbiology at the Vall d’Hebron Institute of Research (VHIR) have participated in the annual meeting of the Spanish net of research in infectious pathology (REIPI). In the meeting, that has reached its seventh edition and this year coincided with the European Antibiotic Awareness Day, experts discussed the recommendations of the European Centre for Disease Prevention and Control about the prudent use of antibiotics. This meeting is an opportunity to launch a global appeal for the problem of antibiotic resistance. </td></tr></table>comunica@vhir.org (VHIR)Tue, 18 Nov 2014 00:00:00 GMTExperts in congenital bone marrow failure meet in VHIR (17/11/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=234&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0234\2014_0234_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Over 70 experts in bone marrow failure field, both national and international, met last Friday, 14th November, in the XXth Pediatric Oncology and Hematology Update Course organized by the Vall d’hebron Institut de Recerca (VHIR). The specialists addressed the latest news in research and clinical practice of these illnesses, deepening the knowledge and diagnostic of population under the risk of suffering cancer. The Research team in Child Cancer, headed by Dr. Josep Sánchez de Toledo, organized once again this meeting, reference in the field. The congress day concluded with Body-Cell Percussion’s performance, by Santi Serratosa and Mariona Castells.  </td></tr></table>comunica@vhir.org (VHIR)Mon, 17 Nov 2014 00:00:00 GMTVHIR researchers discover why the individuals with Down Syndrome have more predisposition to suffer autoimmune diseases (12/11/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=233&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0233\2014_0233_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> A team of researchers of the Immunology group at Vall d’Hebron Institute of Research (VHIR) have discovered that an autoimmune regulator protein, called AIRE, is less expressed in individuals with Down Syndrome. This finding explains why the people with this syndrome have more predisposition to suffer autoimmune diseases. For the study, published in the Journal of Immunology, VHIR researchers used the major collection of thymus samples collected until now. Specifically, they analyzed samples from 19 individuals with Down Syndrome and congenital heart disease, collected since 1995 at the Pediatric Surgery unit of the Vall d’Hebron University Hospital. All thymus were removed following cardiac surgery because in this type of interventions the organ can’t be reintroduced. All samples were compared with the samples of patients with congenital heart disease but without Down Syndrome. The AIRE protein is codified on chromosome 21, which is tripled in individuals with Down Syndrome. Despite having three copies of the chromosome, they have more predisposition to suffer autoimmune diseases such as diabetes, celiac disease and hypothyroidism. To determine which is the role of AIRE in these individuals, Vall d’Hebron researchers analyzed its expression in the thymus. “Contrary to what we expected, we saw that in patients with Down Syndrome the protein is expressed in lower levels that in the rest of the people”, assured Dr. Roger Colobran, main author of the study. As a consequence, the expression of the specific genes that depend on this protein is also reduced, and this produces the central tolerance failure that takes place in the thymus. The origin of many autoimmune diseases is in the thymus, which is the organ of the immune system where the T lymphocytes, that coordinate the immune response, are developed. AIRE controls the mechanism that educates the T lymphocytes to attack external organisms such as virus, bacteria, fungus or parasites, instead of the own cells of the body. However, when this protein is less expressed, there is a central tolerance failure and T cells attack the own cells, which can cause ultimately an autoimmune disease. </td></tr></table>comunica@vhir.org (VHIR)Wed, 12 Nov 2014 00:00:00 GMTCAMFIC allocates the 0.7% of its budget on a project led by VHIR and PROSICS in Angola (12/11/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=176&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0176\2014_0176_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Catalan Society for Family and Community Medicine (CAMIFIC) has donated nearly 12,000 euros, which is the 0.7% of its budget, to the project “Improvement of the treatment and quality of life of patients with tuberculosis in an area of Angola with high prevalence of the disease”, led by researchers from Vall d’Hebron Institute of Research (VHIR) and the International Health Program of the Catalan Institute of Health (PROSICS). The society concluded in a statement that the project was awarded for its research dimension, its commitment to telemedicine and its orientation towards the health co-development. The study is carried out at VHIR by the groups of Infectious Diseases and Microbiology. Since 2008, researchers and clinicians from Vall d’Hebron have worked closely with the Nossa Senhora da Paz Hospital, located in the centre-east of Angola. Since then, they are maintaining a telemedicine program to share clinical cases, and conducting several studies about the resistance to tuberculosis, the epidemiology of schistosomiasis, and the relationship between malaria and child mortality. A couple of months ago, they installed in Angola the first automatic system to diagnose multidrug-resistant tuberculosis, thanks to an agreement with the Probitas Foundation. </td></tr></table>comunica@vhir.org (VHIR)Wed, 12 Nov 2014 00:00:00 GMTDr. Josep Vaqué is awarded with the Semmelweis prize (11/11/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=232&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0232\2014_0232_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Dr. Josep Vaqué, researcher of the Epidemiology and Public Health group at Vall d’Hebron Institute of Research (VHIR) and consultant physician of the same service at the hospital, has received the Semmelweis prize by the Spanish society of preventive medicine, public health and hygiene. The organization has awarded him for his study on the prevalence of hospital-acquired infections in Spain and for his commitment with the development and consolidation of the scientific society. He has coordinated since 1990 this annual study that is carried out in nearly 260 Spanish hospitals to determine the impact of the nosocomial infections in each centre. During the award ceremony, hosted last Friday at the Spanish Department of Health, Social Policy and Equality, Dr. Vaqué assured that “the EPINE study has become a very useful tool for the management of the hospitals, to improve the quality in the health care, and to ease the training of the staff in terms of surveillance, prevention and the control of nosocomial infections”. According to the latest results of the EPINE study, the 5.6% of the inpatients in 2014 got infected in the hospital, compared with the 8.5% in 1990. For Dr. Vaqué, these results show that “hospitals offer every year more security and quality in the control of nosocomial infections, which are still a common problem”. </td></tr></table>comunica@vhir.org (VHIR)Tue, 11 Nov 2014 00:00:00 GMTDr. Schwartz participates in the development of a strategic plan for innovation in nanotechnology in Argentina (06/11/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=231&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0231\2014_0231_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Dr. Simó Schwartz, coordinator of the CIBBIM-Nanomedicine at the Vall d’Hebron Institute of Research (VHIR), has advised the government of Argentina to develop a strategic plan of innovation in the field of nanomedicine and nanotechnology. The international consortium that has guided the government is also participated by the Institut de Bioenginyeria de Catalunya and the Universidad Nacional del Mar del Plata. After identifying the priority lines of research, development and innovations in this field, VHIR researchers have suggested specific action lines as well as political instruments required to implement them through the National plan of Science, Technology and Innovation 2005-2030. Among the main recommendations, there is the creation of national centers, the promotion of clusters, increasing public investments in equipment and R&amp;D&amp;I projects, promotion of entrepreneurship, speeding up import procedures, and the implementation of strategic monitoring systems to identify and create opportunities. Dr. Schwartz will also participate in the follow up of the project, which has received the technical support of IALE Tecnología, and has been funded by the Argentine government and the World Bank. </td></tr></table>comunica@vhir.org (VHIR)Thu, 6 Nov 2014 00:00:00 GMTVHIR is awarded with two 'Premios Mejores Ideas 2014' (04/11/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=230&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0230\2014_0230_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Dr. Ferran Morell, head of the Pneumology group at Vall d’Hebron Institute of Research (VHIR), was awarded with one of the “Premios Mejores Ideas 2014”, by Diario Médico, for the discovery of one of the causes of the idiopathic pulmonary fibrosis. The journal specialized in health also awarded a pioneer surgery carried out at the Vall d’Hebron Hospital and led by Dr. David García Dorado, head of the Cardiocirculatory Pathology group at VHIR. The research conducted by Dr. Morell determined that one of the main causes of the idiopathic pulmonary fibrosis is the exposure of occult avian antigens from commonly used feather bedding (eiderdown and pillows), as well as the exposure to birds and fungi in little but persistent quantities. These surprising results, published in The Lancet Respiratory Medicine, will help the prevention and early detection of this pathology, avoiding advanced stages. On the other hand, Dr. García Dorado coordinated a surgery on a 22 weeks’ pregnant woman, who suffered a congenital heart disease and was wearing a prosthesis that replaced the aortic valve. The prosthesis failed by the stress of the heart during the pregnancy, and consequently, she suffered heart failure and a severe stenosis that put her life and the fetus’ life at risk. The medical team successfully implemented an aortic prosthesis inside the prosthesis that she was already wearing, in order to repair it.  The Catalan national theater (TNC) hosted on Monday the XIII edition of these prizes that recognize outstanding institutions and professionals in the field of healthcare in the last year. Among the winners, the former responsible of the Alzheimer’s group at VHIR, Dr. Mercè Boada, was awarded for starting a phase III clinical trial that could modify the course of the disease and stop the cognitive impairment. </td></tr></table>comunica@vhir.org (VHIR)Tue, 4 Nov 2014 00:00:00 GMTThere are whishes that change the world (03/11/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=229&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0229\2014_0229_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Plaza de Los Pinazo of Valencia will host until November 4, the campaign “There are whishes that change the world” by Legado Solidario. Vall d’Hebron Institute of Research (VHIR) participates in this project with the aim to disseminate the possibility of leaving bequests and legacies to charities and nonprofit organizations. These types of donations have the aim to keep the commitment of those who die and want to support any of the 24 entities associated to the campaign, such as VHIR. The procedure that must be followed to formalize the legacy is inexpensive and simple, and respects the rights of the heirs. The image that represents VHIR is a pregnant woman who holds a picture of a newborn who clutches his parents hand with the slogan “Your legacy will give life to others”. Since the participation of VHIR in the campaign in 2012, 4 people have contributed to the biomedical research of excellence led at Vall d’Hebron, with two bequests and legacies.&nbsp; herencias. </td></tr></table>comunica@vhir.org (VHIR)Mon, 3 Nov 2014 00:00:00 GMTLa Marató de TV3 funds 5 projects in which VHIR participates (30/10/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=228&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0228\2014_0228_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> La Marató de TV3 on Neurodegenerative Diseases will fund 5 projects that will be carried out at the Vall d’Hebron Institute of Research (VHIR) and other research centers. A total of 44 research projects of scientific excellence will be funded with the 11 million euros raised in the 2013 edition. From the 5 projects granted, VHIR will lead 2: “Efecte terapèutic de liposomes conjugats a proteïna ApoJ/Clusterin recombinant en models experimentals de malaltia d'Alzheimer” Principal investigator: Dr. Mar Hernández-Guillamon, researcher of the Neurovascular Diseases group. Budget: 200,000 euros “El paper de la reelina en la cruïlla dels mecanismes moleculars de la malaltia d’Alzheimer: taupatia, toxicitat de l’amiloide i transmissibilitat” Principal Investigator: Dr. Lluís Pujadas, researcher of the Alzheimer’s group. Collaborator: Dr. José María Delgado, from the Universidad Pablo de Olavide de Sevilla Budget: 299.943 euros Besides these projects, VHIR will collaborate in 3: “Desxifrant la relació entre la reactivitat des astròcits i el dany neuronal en la malaltia d'Alzheimer” <span style=" font-size: 8pt; font-family: 'Verdana', 'Geneva', sans-serif; font-style: normal; font-weight: normal; color: #555555; background-color: transparent; tex</td></tr></table>comunica@vhir.org (VHIR)Thu, 30 Oct 2014 00:00:00 GMTVHIR wins Best in Class 2014 to the best research and innovation center (29/10/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=226&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0226\2014_0226_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Vall d'Hebron Institute of Research (VHIR) has received the Best in Class award to the best research and innovation center, one of the prizes organized by the journal Gaceta Médica and the Cátedra de Innovación y Gestión Sanitaria de la Universidad Rey Juan Carlos. The Unit of transplantations of haemopoietic progenitors at Vall d'Hebron University Hospital (HUVH) and the Multiple Sclerosis Center (Cemcat) also have been awarded in a ceremony in which were represented the best hospitals of Spain. This award fits perfectly with the aim of VHIR, which mission describes it as an institution that promotes and developes not only research but also biomedical innovation. VHIR does research to improve people's lives, and its researchers work to transfer to the society the knowledge they got investigating in the&nbsp; labs. Their results don't stay in the labs, but seek to be applied in patients in mid term. Dr. Joan Comella, VHIR's director, received the award in a cerimony that took place in the World Trade Center of Barcelona with the presence of the Catalan Health Minister, Dr. Boi Ruiz. </td></tr></table>comunica@vhir.org (VHIR)Wed, 29 Oct 2014 00:00:00 GMT